Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (CTRI/2026/09/117347) titled 'A study to compare a new biosimilar Daratumumab in combination with Lenalidomide and Dexamethasone, in patients with newly diagnosed multiple myeloma who cannot undergo stem cell transplant' on Sept. 9.
Study Type: Interventional
Study Design:
Other Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Not Applicable Blinding and masking:Not Applicable
Primary Sponsor: Zydus Lifesciences Limited.
Condition:
Health Condition 1: C90- Multiple myeloma and malignant plasma cell neoplasms
Intervention:
Intervention1: Daratumumab [ZRC-3296]: 16 mg/k...